Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and ...
Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination ...
News Medical on MSN11d
UQ and Vaxxas win global prize to accelerate patch-based mRNA vaccine for COVID-19The University of Queensland's BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as ...
Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...
Vaxxas Pty. Ltd. and the Coalition for Epidemic Preparedness Innovations are progressing heat-stable, dried-formulation mRNA ...
BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) ...
PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.
The selection by BARDA recognizes Vaxxas’ significant advancements towards commercializing its proprietary high-density microarray patch (HD-MAP) for vaccine delivery, including completion of ...
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...
The award highlights BioNet's novel mRNA influenza vaccine candidate and its unparalleled manufacturing agility—critical for addressing emerging global health threats. The $50 million Patch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback